EI
JNCE

Ellevest Inc’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Ellevest Inc’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15
Closed – – 1702
2021
Q4 		$0 Hold
15
– – ﹤0.01% 1731
2021
Q3 		$0 Sell
15
-19
-56% -$118 ﹤0.01% 1638
2021
Q2 		$0 Hold
34
– – ﹤0.01% 1456
2021
Q1 		$0 Hold
34
– – ﹤0.01% 1388
2020
Q4 		$0 Buy
+34
New +$265 ﹤0.01% 1406
2020
Q2 		– Sell
-202
Closed -$1K – 1404
2020
Q1 		$1K Buy
202
+30
+17% +$173 ﹤0.01% 1028
2019
Q4 		$2K Buy
+172
New +$930 ﹤0.01% 706

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ellevest Inc's JNCE Position: Q1 2022 in Review

Ellevest Inc sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 15 shares.

Ellevest Inc first reported a position in JNCE in Q4 2019 and held it in 7 quarters. The position peaked at $2K in Q4 2019. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Ellevest Inc reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Ellevest Inc sold 15 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022.
  • Ellevest Inc first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
  • Ellevest Inc's Jounce Therapeutics, Inc. Common Stock position peaked at $2K in Q4 2019.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Ellevest Inc's 13F filing for Q1 2022, filed 19 Apr 2022.